BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

BioTech Health X

450 posts

Biotech NewsZenas BioPharma (ZBIO) is a Rising Star in Autoimmune Drug Development

  • BioTech Health X
  • May 30, 2025
Zenas BioPharma Inc. (NASDAQ:ZBIO) is a clinical-stage biopharmaceutical company boldly pioneering a new frontier in immunology with a…
0 Shares
0
0
0
0
0
0
0

Biotech NewsMBX Biosciences Is Building the Future of Hormone Therapy

  • BioTech Health X
  • May 30, 2025
MBX Biosciences Inc. (NASDAQ:MBX) is gaining attention in the biotech investment landscape as a rising leader in peptide-based…
0 Shares
0
0
0
0
0
0
0

Biotech NewsBicara Therapeutics (BCAX) is a High-Potential Biotech Stock in 2025

  • BioTech Health X
  • May 30, 2025
Bicara Therapeutics Inc. (NASDAQ: BCAX) is a clinical-stage biotechnology company redefining the future of cancer treatment through its…
0 Shares
0
0
0
0
0
0
0

Biotech NewsCrinetics Pharmaceuticals (CRNX) Could Be the Next Biotech Breakout

  • BioTech Health X
  • May 30, 2025
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is a leading clinical-stage biotechnology company dedicated to revolutionizing the treatment landscape for rare…
0 Shares
0
0
0
0
0
0
0

Biotech NewsCandel Therapeutics (CADL) is a Rising Star in Cancer Immunotherapy

  • BioTech Health X
  • May 30, 2025
Candel Therapeutics Inc. (NASDAQ:CADL) is a clinical-stage biopharmaceutical company pioneering a new class of cancer immunotherapies that leverage…
0 Shares
0
0
0
0
0
0
0

Biotech NewsOramed (ORMP) Eyes Comeback with Oral GLP-1 and NASH Pipeline Expansion

  • BioTech Health X
  • May 30, 2025
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) is a clinical-stage biopharmaceutical company that is redefining the treatment landscape for chronic diseases…
0 Shares
0
0
0
0
0
0
0

Biotech NewsOrganovo (ONVO) is a Smart Long-Term Investment

  • BioTech Health X
  • May 30, 2025
Organovo Holdings, Inc. (NASDAQ: ONVO) is a trailblazing biotechnology company headquartered in San Diego, California, that is redefining…
0 Shares
0
0
0
0
0
0
0

Biotech NewsAdverum Biotechnologies (ADVM) is the Future of Vision-Restoring Gene Therapy

  • BioTech Health X
  • May 30, 2025
Adverum Biotechnologies Inc. (NASDAQ:ADVM) is a clinical-stage biotechnology company pioneering the next generation of gene therapy solutions to…
0 Shares
0
0
0
0
0
0
0

Biotech NewsBreakthrough Immunotherapy From Agenus (AGEN) Targets Toughest Tumors in 2025

  • BioTech Health X
  • May 27, 2025
Agenus Inc. (NASDAQ:AGEN) is emerging as one of the most promising biotech companies focused on immuno-oncology, with a…
0 Shares
0
0
0
0
0
0
0

Biotech NewsProQR Therapeutics (PRQR) is a Game-Changer in Precision RNA Editing

  • BioTech Health X
  • May 27, 2025
ProQR Therapeutics N.V. (NASDAQ:PRQR) is a clinical-stage biotechnology company blazing a new trail in the world of precision…
0 Shares
0
0
0
0
0
0
0

Biotech NewsArcturus Therapeutics (ARCT) is a Smart Long-Term Bet in Biotech

  • BioTech Health X
  • May 27, 2025
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is redefining the future of RNA medicines with a powerful blend of science,…
0 Shares
0
0
0
0
0
0
0

Biotech NewsEditas Medicine (EDIT) is a Top Gene Editing Stock to Watch in 2025

  • BioTech Health X
  • May 27, 2025
Editas Medicine Inc. (NASDAQ:EDIT) is a clinical-stage biotechnology firm leading the charge in the development of CRISPR-based gene…
0 Shares
0
0
0
0
0
0
0

Biotech NewsAlnylam Pharmaceuticals is a Stock to Buy: Eyes $2.25 Billion in 2025 Revenue

  • BioTech Health X
  • May 26, 2025
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is a trailblazing biopharmaceutical company that has redefined modern medicine by pioneering the development…
0 Shares
0
0
0
0
0
0
0

Biotech NewsIonis Pharmaceuticals (IONS) Is a Bullish Biotech Bet in 2025

  • BioTech Health X
  • May 26, 2025
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) is a pioneering force in the field of RNA-targeted therapeutics, recognized globally for its…
0 Shares
0
0
0
0
0
0
0

Biotech NewsBluebird Bio (BLUE) Posts 108% Revenue Growth in Q1 2025 Amid Acquisition Buzz

  • BioTech Health X
  • May 26, 2025
Bluebird bio Inc. (NASDAQ:BLUE) is a trailblazing biotechnology company that has spent more than a decade at the…
0 Shares
0
0
0
0
0
0
0

Biotech NewsIncyte (INCY) is the Next Big Biotech Winner

  • BioTech Health X
  • May 25, 2025
Incyte Corporation (NASDAQ:INCY) is a globally recognized, innovation-driven biopharmaceutical company committed to discovering, developing, and commercializing novel therapeutics…
0 Shares
0
0
0
0
0
0
0

Biotech NewsNeurocrine (NBIX) is a Stock to Buy

  • BioTech Health X
  • May 25, 2025
Neurocrine Biosciences Inc. (NASDAQ:NBIX) is a leading neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing treatments…
0 Shares
0
0
0
0
0
0
0

Biotech NewsGilead Sciences (GILD) is a Top Long-Term Biotech Investment for 2025

  • BioTech Health X
  • May 25, 2025
Gilead Sciences Inc. (NASDAQ:GILD) is a leading global biopharmaceutical company renowned for its transformative contributions to antiviral medicine…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Insmed (INSM) Jumps to $149.20 High After FDA Approval of Brinsupri
  • Ocular Therapeutix (OCUL) Raises $475M to Fund Phase 3 Axpaxli Trials
  • Novavax (NVAX) Expands $200M Sanofi Deal With Matrix-M Adjuvant
  • Recursion Pharmaceuticals (RXRX) Could Double With $8 Price Target
  • Dermata (DRMA) Wins Australian Patent for Acne Therapy
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • October 3, 2025
    Insmed (INSM) Jumps to $149.20 High After FDA Approval of Brinsupri
    • October 3, 2025
    Ocular Therapeutix (OCUL) Raises $475M to Fund Phase 3 Axpaxli Trials
    • October 3, 2025
    Novavax (NVAX) Expands $200M Sanofi Deal With Matrix-M Adjuvant
    • October 3, 2025
    Recursion Pharmaceuticals (RXRX) Could Double With $8 Price Target
    • October 2, 2025
    Dermata (DRMA) Wins Australian Patent for Acne Therapy
Recent Posts
  • Kazia (KZIA) Trades Under $1 While Tackling Cancers With <1-Year Survival Rates
    • October 2, 2025
  • CorMedix (CRMD) Revenue to Hit $350M After Melinta Buyout
    • October 2, 2025
  • Halozyme (HALO) Reports $1.179B Revenue and 65% Royalty Growth
    • October 2, 2025
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (1)
  • Biotech News (439)
  • Uncategorized (1)
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top